Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary ...

Tickets are on sale for the 40th anniversary of the PM Awards! Book now and join us on Friday 20 th March 2026 at the JW ...

In a wide-ranging sit down during JP Morgan Week in San Francisco, Astellas' chief strategy officer Adam Pearson walked ...

Hopstem has already completed phase 1 testing of hNPC01 in China, with encouraging results, and says it has now reached ...

That closes out our agency round-up for last year, but stay tuned for our other hires round-ups and remember, you can send ...

Industry reports the Saudi pharmaceutical CDMO market is expected to increase from USD $1.62 billion in 2024 to USD $2.24 ...

At the moment, Teizeild is indicated only for use in patients aged eight and over, but Sanofi has already filed for approval ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

In a new pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

Under the terms of the J&J deal, Isomorphic will be responsible for in silico predictions and design, while the US group will ...